These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35072890)

  • 21. Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.
    Sun X; Liu Q; Tang X; Yao K; Li Y; Yang J; Zhang M; Yuan H; Zheng Y; Li W; Peng H
    BMC Ophthalmol; 2022 Aug; 22(1):332. PubMed ID: 35932001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
    Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
    Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
    Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
    BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
    Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
    BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
    Matsuo M; Matsuoka Y; Tanito M
    Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
    Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE
    Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.
    Wang K; Xu L; Yuan Z; Yao K; Zhao J; Xu L; Fang A; Zhang M; Wu L; Ji J; Hou J; Liu Q; Sun X
    BMC Ophthalmol; 2014 Feb; 14():21. PubMed ID: 24568617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
    Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
    J Ocul Pharmacol Ther; 2022 Jun; 38(5):354-358. PubMed ID: 35613407
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
    Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
    J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Berdahl JP; Sarkisian SR; Ang RE; Doan LV; Kothe AC; Usner DW; Katz LJ; Navratil T;
    Drugs; 2024 Jan; 84(1):83-97. PubMed ID: 38060092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Periocular Adverse Reactions to Omidenepag Isopropyl.
    Inoue K; Shiokawa M; Katakura S; Tsuruoka M; Kunimatsu-Sanuki S; Shimizu K; Ishida K; Tomita G
    Am J Ophthalmol; 2022 May; 237():114-121. PubMed ID: 34942112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Zaman F; Gieser SC; Schwartz GF; Swan C; Williams JM
    Curr Med Res Opin; 2021 Jun; 37(6):1011-1020. PubMed ID: 33733980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
    Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.
    Shiratori N; Nishio Y; Takeda A; Sugimoto S; Takazawa K; Otsuka N; Ishida N; Shii D; Hori K; Nakamoto K
    Clin Ophthalmol; 2021; 15():3997-4003. PubMed ID: 34675468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.